Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,623 across all filing types
Latest filing 2026-03-29 Report Publication Anno…
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 90% confidence The document is extremely short (242 characters) and merely states that an announcement has been published on the website. It does not contain any substantive report content itself, but simply notifies readers of a published document. This matches the criteria for a Report Publication Announcement (RPA) under the “menu vs. meal” rule.
2026-03-29 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 80% confidence The document is extremely brief (242 characters) and merely states that an announcement has been published in the Chinese section of the website. It contains no substantive report content—only a notice of publication. Under the “menu vs. meal” rule, this is not the report itself but an announcement that a report/filing has been made available. Therefore, it best fits the Report Publication Announcement category (RPA).
2026-03-29 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 85% confidence The document is extremely short and states only that an announcement has been published by the issuer, without containing any report content itself. It is notifying readers of a publication rather than providing substantive report details. According to the menu vs. meal rule, this is a Report Publication Announcement.
2026-03-29 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 68% confidence The document is extremely short and simply states that an announcement has been published in another section of the website, without providing substantive content itself. This fits the pattern of a Report Publication Announcement (RPA) under the 'menu vs meal' rule rather than a full report or specific filing.
2026-03-29 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025
Annual Report Classification · 95% confidence The document is titled 'ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025' and contains detailed financial data including revenue, profit, expenses, and cash equivalents for the year ended December 31, 2025. It also includes a comprehensive management discussion and analysis section, business highlights, product pipeline updates, and clinical trial progress. The length of the document is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. The content aligns with a full yearly report covering company activity and financial performance. Therefore, this document fits the definition of an Annual Report (10-K).
2026-03-27 English
VOLUNTARY ANNOUNCEMENT - Approval of the New Drug Application for Disitamab Vedotin for the Indication of HER2-Low Breast Cancer with Liver Metastases
Regulatory Filings Classification · 75% confidence The document is a voluntary announcement on the Hong Kong Exchange regarding the regulatory approval of a new drug indication. It does not report financial results, management changes, share transactions, dividends, or M&A, nor is it an investor presentation or interim report. It is a regulatory disclosure that does not fit any more specific category, making it a general regulatory filing (RNS).
2026-03-23 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.